GNPX News and Press, Genprex Inc. From 06/25/20

Genprex (NASDAQ: GNPX ) announces that the United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex immunogene therapy for non-small cell lung cancer. More news on: Genprex, Inc., Healthcare stocks new...

Company executes on corporate communication strategy and advances drug branding initiatives Lead drug candidate for NSCLC now referred to as quaratusugene ozeplasmid or GPX-001 Company rebrands use of Oncoprex™ name for Nanoparticle Delivery Platform Genprex, Inc. (...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its CEO and Chairman, Rodney Varner, will be participating in a live interview with the “Big Biz Show,” an...

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that its Chairman and Chief Executive Officer, Rodney Varne...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the man...

Expansion enables full commercial scale plasmid DNA manufacturing capabilities Manufacturing program supports upcoming clinical trials, including Oncoprex in combination with Tagrisso®, which received FDA Fast Track Designation Genprex, Inc. (“Genprex” or the...

The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the 3,000 publicly traded companies on ...

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the upda...